Solve GNE Advances First Gene Therapy for GNE Myopathy Toward Phase I Clinical Trial
核心洞察
Solve GNE (搜索) has raised over $6.5 million and is pursuing up to $10.2 million in federal grants to advance the first gene therapy for GNE myopathy (搜索) toward clinical testing.
Preclinical studies demonstrate that a dual-function plasmid successfully restores GNE (搜索) protein expression and increases sialic acid (搜索) production in animal models when delivered intravenously.
The nonprofit foundation plans to file an IND application in 2026 with Gradalis Inc. (搜索), targeting first-in-human dosing within 12 months pending FDA clearance.
Solve GNE (搜索), a nonprofit foundation dedicated to accelerating treatments for GNE myopathy (搜索), has announced significant progress toward launching the first gene therapy clinical trial for this rare neuromuscular disease. The organization has raised more than $6.5 million to date and is pursuing approximately $10.2 million in potential federal funding to support multiple research programs aimed at bringing clinically viable therapies to patients.
Preclinical Data Shows Promise for Dual-Function Gene Therapy
A newly published preclinical study conducted in collaboration with Gradalis Inc. (搜索) demonstrates the potential of an innovative gene therapy approach for GNE myopathy (搜索). The research describes a dual-function plasmid called GNEwt/bi-shRNA-GNEM743T lipoplex (搜索), which simultaneously delivers the wild-type GNE (搜索) gene and shuts off expression of GNEM743T (搜索), a mutation highly prevalent in the Iranian Jewish community.
The preclinical data showed that this approach leads to clinically relevant expression levels of functioning GNE (搜索) protein and increased sialic acid (搜索) production. The lack of sialic acid production is a hallmark of GNE myopathy (搜索) and is suspected to be the leading cause of muscle loss in patients with this condition.
Animal model studies demonstrated successful delivery of the engineered plasmid to muscle tissue following intravenous administration using a DOTAP-cholesterol lipoplex formulation. These findings support continued development of the gene therapy and establish a foundation for future clinical testing.
Regulatory Progress and Clinical Timeline
Solve GNE (搜索) is directing funding toward the filing of an Investigational New Drug (IND) application by Gradalis Inc. (搜索) in 2026. The FDA has already reviewed and provided comments on the pre-IND application, and the team is currently finalizing the IND submission for what would be the first gene therapy targeting GNE myopathy (搜索).
The organization anticipates that a Phase I clinical trial may begin within the next 12 months following IND approval. This timeline positions the program to be the first gene therapy to enter clinical testing for GNE myopathy (搜索).
Comprehensive Research Portfolio
Beyond the lead gene therapy program, Solve GNE (搜索) is pursuing several grant opportunities to support next-phase research and development. These applications focus on developing safer AAV-based gene therapies, novel blood-based biomarkers, gene editing approaches, validation of a diagnostic platform to predict immune responses to AAV-based therapies, and further development of a clinically scalable dbRNA lipoplex treatment.
The dual-function design of the lead therapy addresses a founder variant common in a key subpopulation, potentially improving molecular precision and reducing efficacy risks in early patient cohorts. The nonviral lipoplex formulation could also mitigate challenges associated with pre-existing capsid immunity and redosing that complicate AAV programs.
Strategic Focus on Rare Disease Development
The approach represents a focused, multimodal strategy by a disease-specific nonprofit to accelerate clinical development while maintaining optionality across different delivery modalities. Solve GNE (搜索)'s commitment to funding additional research aims to build a stronger pathway toward future treatment options for patients with this rare neuromuscular condition.
The organization's comprehensive strategy includes parallel development of complementary technologies and biomarkers, positioning multiple potential therapeutic approaches for this underserved patient population. Success in the upcoming clinical trial could establish an important precedent for gene therapy development in rare neuromuscular diseases.